XOMA Royalty Corporation

NASDAQ: XOMA
Share price (2/14/25): $26.76
Market cap (2/14/25): $315 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 09/30/24 Q3

ended 06/30/24 Q2

ended 03/31/24 Q1

ended 12/31/23 FY 2023

ended 09/30/23 Q3

Prospectuses and Registrations Filter

Third party tender offer – amended

Third party tender offer – amended

Details of business combination or exchange offer

Shelf registration

Third party tender offer

Ownership Filter

Biotechnology Value Fund L P, Bvf Partners L P/Il, Bvf Inc/Il, Biotechnology Value Fund II LP, Lampert Mark N, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., Bvf I GP LLC, Bvf II GP LLC, Bvf GP Holdings LLC

Biotechnology Value Fund L P

Burns Thomas M.

News Filter

Pulmokine, Inc. Financial Statements December 31, 2023 Pulmokine, Inc. Index to the Financial Statements December 31, 2023

Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio

Reports Third Quarter 2024 Financial Results and Highlights Recent Activities

Significantly Expands Its Royalty and Milestone Portfolio With the Addition of Over 60 Early-Stage Programs From Twist Bioscience

Zevra’s MIPLYFFA™ (Arimoclomol) Receives Approval From U.S. Food and Drug Administration for Use in Patients With Niemann-Pick Disease Type C

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Other Filter

Notice of effectiveness

Notice of effectiveness

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC